2024-05-23 03:32:00
Antimicrobial resistance, the new report from the Access to Medicine Foundation explains what pharmaceutical companies can do
THE Access to the Medicine Foundation has released a new report on how a shift in research and development (R&D) and greater investment in access planning and stewardship can make a difference in the fight against antimicrobial resistance (AMR). Today, few large pharmaceutical companies invest in Antimicrobial R&Dmeaning very few new treatments come to market, leaving patients vulnerable to the expansion of antimicrobial resistance.
The study highlights five promising projects in advanced clinical development: GSK, F2G, He was innovating, Venatorx (gepotidacin, olorofim, zoliflodacin and cefepime-taniborbactam, respectively) and aztreonam-avibactam (Emblaveo®) recently approved by Pfizer. Treatments that could save at least 160,000 lives every yeareffectively addressing drug-resistant gonorrhea, urinary tract infections, intra-abdominal infections, respiratory infections and invasive fungal infections.
The diseases cited in the report affect a wide range of patients globally, with a strong impact on women and children in low- and middle-income countries (LMICs). Jayasree K. IyerCEO of Access to the Medicine Foundationcommented: “We have a small but effective arsenal in the race to fight drug-resistant infections. The difference between winning or losing this race depends on how companies provide access to people living on the front lines of drug resistance“.
The report shows that companies are adopting various strategies in their access and management plans, but structured advance planning is not yet a common standard. It is encouraging to note that Pfizer, GSK, He was innovating And Venatorx are conducting or launching clinical trials aimed directly at children, reporting progress in bridging the gap between adult and pediatric access. Commitments to register new treatments were also made in five low- and middle-income countries: China, India, Mexico, South Africa and Thailand. However, for 108 of the 113 LMICs involved, it is not yet clear whether the new drugs will be made available after initial approval.
“Addressing the scale and pace of drug resistance is a complex global health problem that will require intervention from pharmaceutical companies across multiple sectors. This includes providing adequate access and implementing management measures to safeguard the effectiveness of innovative antimicrobials. Failure to do so will limit efforts to counter drug resistance“he declared Marijn VerhoefDirector of Operations and Research, Access to the Medicine Foundation.
As the global community prepares for the 2024 United Nations General Assembly high-level meeting on antimicrobial resistancethe report highlights urgent gaps that need attention. The recommendations and actionable measures outlined represent an opportunity to promote the adoption of early access and stewardship strategies, helping to ensure that essential medicines reach those who need them most.
#Antimicrobial #resistance #Access #Medicine #Foundation #report #shows #pharmaceutical #companies